Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1871)	8/28/2007 9:29:08 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ADLR Is also doing well in PM after it announced that the FDA has accepted its response to the Nov.2006 NDA for Entereg for postoperative ileus. biz.yahoo.com The stock is up 15.7% in PM. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1871)	9/24/2007 4:26:21 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

XOMA Continues on the up-move that started on Aug28 when it announced that it had licensed to PFE non-exclusive rights to its BCE technology for phage display & other research & development of antibody products, for an upfront cash payment of $30M & milestone & royalty fees on future sales of products subject to this license. The stock was up 17.8% at 3:25PM, but closed up only 12% <g> bigcharts.marketwatch.com In July XOMA started a P1 in the U.S. of XOMA-052 in Type 2 diabetes & on Sep12, it announced that it started a second P1 of XOMA-052 in Europe. XOMA-052 is a monoclonal antibody targeting IL-1 beta in patients with Type 2 diabetes. IL-1 plays a role in many inflammatory diseases and has been implicated in the pathogenesis of Type 2 diabetes through the destruction of the pancreatic islet cells. Besides Type 2 diabetes, XOMA has plans to test XOMA-052 in patients with other inflammatory conditions,including RA & osteoarthritis. The stock needs to close above its Apr23 H of 3.80 (today's intra-day H was 3.77)to resume the longer term uptrend that started in Sep2006 from the 1.70 level.If it can do that, the near term target is around 4.80 (That would be a 33.7% gain from present levels.<g>) bigcharts.marketwatch.com Bernard